Fulgent Genetics, Inc.
FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancerā¦ read more
Healthcare
Diagnostics & Research
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$29.10
Price-1.66%
-$0.49
1Y
Price
Market Cap
$893.237m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-18.9%
EBITDA Margin-23.2%
Net Profit Margin-45.2%
Free Cash Flow MarginRevenue
$303.223m
+7.0%
1y CAGR-16.1%
3y CAGR-21.5%
5y CAGREarnings
-$51.023m
-19.5%
1y CAGR-54.0%
3y CAGR-58.4%
5y CAGREPS
-$1.65
-17.0%
1y CAGR-54.5%
3y CAGR-58.8%
5y CAGRBook Value
$1.112b
$1.200b
Assets$88.202m
Liabilities$7.386m
DebtDebt to Assets
0.6%
-0.2x
Debt to EBITDAFree Cash Flow
-$59.952m
-211.4%
1y CAGR-270.3%
3y CAGR-216.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company